Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$5.57 USD
0.00 (-0.02%)
Updated Aug 5, 2025 10:11 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRCA 5.57 0.00(-0.02%)
Will VRCA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Other News for VRCA
VRCA Trading Halted: Anticipation Builds for Pending Announcement | VRCA Stock News
Verrica Parmaceuticals trading halted, news pending
12 Health Care Stocks Moving In Thursday's After-Market Session
Verrica Pharmaceuticals (VRCA) Reports Robust Growth in YCANTH Sales
Verrica Pharmaceuticals reports 13,434 YCANTH dispensed applicator units in Q2